EZH2 and cancer: These PROTACs link a selective EZH2 inhibitor to the CRBN ligand 4-hydroxythalidomide and can degrade the proteasome of the PRC2 subunit in multiple cancer cell types, including EZH2, EED, SUZ12, and Retinoblastoma-binding protein 48 that can completely block EZH2.